Table 2.
Cell potency of rIFN-λ1 cytokines against various HCV subgenomic replicon variants
| HCV GT (replicon cell line) | Compound EC50a |
|||
|---|---|---|---|---|
| rIFN-λ1 | ASV | DCV | NS5B I | |
| 1a (H77) | 4.6 ± 1.5 | 9.4 ± 3.2 | 0.055 ± 0.011 | 4.6 ± 1.5 |
| 1a-NS3-R155K | 1.6 ± 0.6 | 359 ± 63 | 0.073 ± 0.005 | 1.6 ± 0.6 |
| 1a-NS5A-Q30E | 7.0 ± 0.7 | 7.4 ± 0.7 | 447 ± 10 | 7.0 ± 0.7 |
| 1a-NS5A-L31V | 5.7 ± 0.6 | 5.9 ± 0.8 | 121 ± 4 | 5.7 ± 0.6 |
| 1a-NS5A-Y93H | 4.4 ± 1.0 | 7.2 ± 0.5 | 246 ± 3 | 4.4 ± 1.0 |
| 1b (Con1) | 3.3 ± 0.5 | ND | ND | 5.5 ± 1.2 |
| 1b-NS5B-P495L | 2.7 ± 0.7 | ND | ND | 2648 ± 378 |
a
Data are in ng/ml for rIFN-λ1 and nM for ASV, DCV, and NS5B I. ND, not determined. Data indicate the mean EC50 value ± standard deviation from at least three independent experiments.